Highbridge Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Highbridge Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,700	Closed	-$1.28M	–	323
2025 Q1	$1.28M	Buy	+9,700	New	+$1.21M	0.05%	87

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highbridge Capital Management's ITCI Position: Q2 2025 in Review

Highbridge Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 142,280 shares — an estimated $18.8M sold.

Highbridge Capital Management first reported a position in ITCI in Q3 2015 and held it in 5 quarters. The position peaked at $18.8M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Highbridge Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Highbridge Capital Management sold 142,280 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.8M.
Highbridge Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 5 quarters.
Highbridge Capital Management's Intra-Cellular Therapies Inc. position peaked at $18.8M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Highbridge Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.